

Brookline Capital Markets' Senior Biotechnology Analyst Kemp Dolliver Discusses Bellerophon Therapeutics and Outlook Therapeutics with Bloomberg BNN

New York, NY - Brookline Capital Markets' Senior Analyst and Director of Research, Kemp Dolliver, recently spoke with Bloomberg BNN about recent trends in the biotech sector, including the rising cost of capital for companies within the industry.

Kemp discussed the various strategies biotech companies have employed to cut costs and continue the clinical development of assets. He noted that Bellerophon Therapeutics, a clinical-stage biotherapeutics company, has navigated these headwinds with success, having recently raised capital from a prominent biotech investor, which has contributed to an increase in investor confidence. In addition, the company is expecting results from a Phase 3 trial for lung disease in mid-2023, further fueling the positive outlook for the company.

"The cost of capital for this industry has gone up substantially," says Dolliver. "This has been felt most by companies that do not yet have products on the market and will need to raise additional capital, so Bellerophon and many other stocks like it have been under pressure during this time."

Bellerophon Therapeutics' shares have soared **1390%** since hitting 52-week lows in December.

Mr. Dolliver also noted his positive outlook on Outlook Therapeutics, which should launch LYTENAVA for the treatment of advanced age-related macular degeneration (wet AMD) later this year.

To access the complete interview, please follow the link below:

<https://www.bnnbloomberg.ca/video/post-covid-outlook-for-biotech-stocks-analyst-actions~2670083>

Contact:

Brookline Capital Markets:
600 Lexington Avenue, 30th Floor
New York, New York 10022
(646) 603-6716
www.brooklinecapmkts.com

Bellerophon Therapeutics:
20 Independence Boulevard, Suite 402
Warren, NJ 07059
(908) 574-4770
www.bellerophon.com

Outlook Therapeutics:
485 Route 1 South, Building F, Suite 320
Iselin, NJ 08830
(609) 619 3990
www.outlooktherapeutics.com

Disclaimer

Kemp Dolliver has no financial interest in the debt or equity securities of the subject companies. Further, no member of his household has any financial interest in the securities of the subject companies. Neither the analyst, nor any member of his household is an officer, director, or advisory board member of the issuer(s) or has another significant affiliation with these issuers. The analyst has not received compensation from the subject companies. At the time of this interview, the analyst does not know or have reason to know of any other material conflict of interest.

Brookline Capital Markets is a division of Arcadia Securities, LLC. Arcadia Securities, LLC is a member of FINRA and SIPC. Brookline Capital Markets, a division of Arcadia Securities, LLC, has not managed or co-managed a public offering for Bellerophon Therapeutics and has not received compensation for investment banking activity from the company in the 12 months prior to publication. Brookline Capital Markets, a division of Arcadia Securities, LLC, has not managed or co-managed a public offering for Outlook Therapeutics and has received compensation for investment banking activity from the company in the 12 months prior to publication. Brookline Capital Markets, a division of Arcadia Securities, LLC, expects to receive or intends to seek investment banking business from the subject company in the next three months. Arcadia Securities does not hold a beneficial ownership of more than 1% or more of any class of common equity securities of the subject company. Arcadia Securities does not make a market in the securities of the subject company of this report at the time of publication. Arcadia Securities is unaware of any other material conflict of interest of the research analyst or an associated person of the member with the ability to influence the content of this interview.